^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)

    i
    Other names: NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, receptor, type 1
    18h
    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Keytruda (pembrolizumab) • VMD-928
    7d
    Surgical resection and targeted therapy in a pediatric NTRK-rearranged low-grade spindle cell sarcoma: a case report. (PubMed, Childs Nerv Syst)
    This case underscores the importance of integrating molecular diagnostics into the evaluation of atypical spindle cell tumors, particularly those presenting with aggressive clinical features despite low-grade histology. Early identification of NTRK fusions enables timely initiation of TRK inhibitor therapy, offering durable disease control and functional recovery. Broader awareness and implementation of molecular testing can greatly enhance the management of rare pediatric sarcomas.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • TPM3 (Tropomyosin 3) • CD34 (CD34 molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    10d
    ADVL1823: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Jul 2027
    Trial completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6)
    |
    Vitrakvi (larotrectinib)
    15d
    A Prognostic Neuromodulation-Related Gene Signature Identifies Immunomodulation and Tumour-Associated Hallmarks in Glioblastoma. (PubMed, Biomedicines)
    Additionally, high expressions of the 10-NMRGs were noted in the mesenchymal GBM subtype. Collectively, our analysis highlights the potential use of the 10-NMRG signature to stratify the high-risk GBM group with a strong association of immunomodulation and tumour-associated hallmarks that can contribute to the poor survival outcomes.
    Journal • Gene Signature
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • IGF2 (Insulin-like growth factor 2) • EDNRB (Endothelin Receptor Type B) • KCNN4 (Potassium Calcium-Activated Channel Subfamily N Member 4) • OSMR (Oncostatin M Receptor)
    15d
    Comprehensive Molecular Diagnostic Tests in Non-Small Cell Lung Cancer: Frequency of ALK, ROS1, RET, and Other Gene Fusions/Rearrangements in a Romanian Cohort. (PubMed, Cancers (Basel))
    These alterations were mutually exclusive with common drivers such as EGFR or KRAS. Detection of rare fusions highlights the therapeutic potential of comprehensive NGS profiling in Romanian NSCLC patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • EML4 (EMAP Like 4) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD74 (CD74 Molecule) • TACC3 (Transforming acidic coiled-coil containing protein 3) • ETV6 (ETS Variant Transcription Factor 6) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
    |
    EGFR mutation • EGFR L858R • ALK positive • RET fusion • ALK fusion • ROS1 fusion
    |
    Oncomine Focus Assay
    16d
    TPM3-NTRK1 Fusion Cervical Sarcoma: A Case Report of a Novel Subset of Gynaecological Sarcomas and Successful Treatment of Recurrent Disease With Trk-Inhibition Therapy. (PubMed, Cureus)
    The patient remains stable with no evidence of local, nodal, or metastatic disease for more than three years following the initial presentation. This report aims to propose the use of larotrectinib as a management option for recurrent NTRK-positive cervical sarcomas.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • TPM3 (Tropomyosin 3) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Vitrakvi (larotrectinib)
    17d
    Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. (PubMed, Transl Oncol)
    Our study reveals a novel mechanism by which the NOTCH2-NTRK1 fusion confers resistance to osimertinib through its interaction with EGFR in NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NOTCH2 (Notch 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • NTRK fusion
    |
    Tagrisso (osimertinib) • Rozlytrek (entrectinib)
    19d
    Tropomyosin 3 Gene Fusions in Cancers: From Mechanisms to Treatments-A Comprehensive Review. (PubMed, Cancer Med)
    By synthesizing current evidence, this review aims to provide insights into the diagnostic, prognostic, and therapeutic landscape of TPM3-related gene fusions, fostering advancements in precision oncology.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • TPM3 (Tropomyosin 3)
    |
    ALK fusion • ROS1 fusion
    19d
    Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific and Neo-antigens in Follicular Cell-derived Thyroid Cancers. (PubMed, J Clin Endocrinol Metab)
    Our studies confirm the presence of tumor antigen-specific T cells in patients with thyroid cancer and encourage further exploration of T cell-targeted immunotherapies for patients with progressive, treatment refractory thyroid cancer.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CCDC6 (Coiled-Coil Domain Containing 6) • IFNG (Interferon, gamma) • TRB (T Cell Receptor Beta Locus)
    |
    BRAF V600E • BRAF V600
    21d
    DB-1311-O-1001: A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=862, Recruiting, DualityBio Inc. | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Sep 2027 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD276 (CD276 Molecule)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12
    |
    Xtandi (enzalutamide) • abiraterone acetate • itraconazole • BNT324 • ritonavir
    22d
    Coverage of Actionable Alterations In Non-Small Cell Lung Cancer by Hybrid Capture-Based FoundationOne®CDx Compared With Amplicon-based Oncomine™ DX. (PubMed, Oncologist)
    In summary, in advanced NSCLC, hybrid capture-based NGS, such as F1CDx, may capture more actionable genomic alterations as compared with ODxTT, an amplicon-based NGS.
    Journal • Tumor mutational burden • MSi-H Biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    KRAS mutation • EGFR mutation • MSI-H/dMMR • KRAS G12C • MET mutation • KRAS G12
    |
    FoundationOne® CDx • Oncomine™ Dx Target Test
    30d
    NAVIGATE: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (clinicaltrials.gov)
    P2, N=215, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Vitrakvi (larotrectinib)